Microbot Medical reported a decrease in revenue for the third quarter of 2026.
The company posted a revenue of $72,000 for the quarter (end-September 30), down from $241,000 in the second quarter, citing the timing of customer reorders, lower activity during the summer months, and potential new accounts still in hospital value analysis committee review.
Cost of goods sold rose 24% from the second quarter, largely due to an inventory write-down, resulting in a negative gross margin for the period, Microbot said. Systems sold during the quarter also primarily reflected units manufactured in earlier periods at higher production costs, though the manufacturing cost per unit of systems produced in the third quarter continued to decline, according to the company.
Microbot said it expects cost reduction initiatives and a planned second manufacturing line to help it achieve a positive gross margin in 2027.
The vendor also reported that procedure utilization of its Liberty endovascular robotic system rose 44% from the second quarter, and the firm ended the period with 12 customer accounts, up from 10.



















